256 related articles for article (PubMed ID: 37515921)
1. Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension.
Panchal J; Jaiswal S; Jain S; Kumawat J; Sharma A; Jain P; Jain S; Verma K; Dwivedi J; Sharma S
Eur J Med Chem; 2023 Nov; 259():115681. PubMed ID: 37515921
[TBL] [Abstract][Full Text] [Related]
2. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Hamidi SA; Lin RZ; Szema AM; Lyubsky S; Jiang YP; Said SI
Respir Res; 2011 Oct; 12(1):141. PubMed ID: 22029879
[TBL] [Abstract][Full Text] [Related]
3. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
4. Myocardial and anti-inflammatory effects of chronic bosentan therapy in monocrotaline-induced pulmonary hypertension.
Fontoura D; Oliveira-Pinto J; Tavares-Silva M; Leite S; Vasques-Nóvoa F; Mendes-Ferreira P; Lourenço AP; Leite-Moreira AF
Rev Port Cardiol; 2014 Apr; 33(4):213-22. PubMed ID: 24780128
[TBL] [Abstract][Full Text] [Related]
5. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.
Sauvageau S; Thorin E; Villeneuve L; Dupuis J
Pulm Pharmacol Ther; 2009 Aug; 22(4):311-7. PubMed ID: 19489130
[TBL] [Abstract][Full Text] [Related]
6. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
Oldfield V; Lyseng-Williamson KA
Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
[TBL] [Abstract][Full Text] [Related]
7. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
Musch A
Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
[TBL] [Abstract][Full Text] [Related]
8. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
[TBL] [Abstract][Full Text] [Related]
9. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
10. Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Serasli E; Michaelidis V; Kosmas A; Antoniadou M; Tsara V
Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):184-95. PubMed ID: 20874675
[TBL] [Abstract][Full Text] [Related]
11. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Cheng J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
[TBL] [Abstract][Full Text] [Related]
12. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Martynyuk TV; Aleevskaya AM
Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
[TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
Fine N; Dias B; Shoemaker G; Mehta S
Can J Cardiol; 2009 Mar; 25(3):e63-8. PubMed ID: 19279988
[TBL] [Abstract][Full Text] [Related]
15. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
16. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Steiner MK; Preston IR
Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q; Guo N; Chen J; Parks D; Tian Z
J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
[TBL] [Abstract][Full Text] [Related]
19. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
20. Bosentan: a dual endothelin receptor antagonist.
Rubin LJ; Roux S
Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
